Trial Profile
MODULATION OF POSTPRANDIAL LIPEMIA, INFLAMMATION, AND VASCULAR FUNCTION BY PCSK9 INHIBITION IN DIABETES
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2021
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Acronyms PLEIADES-pcsk9
- 11 May 2017 New trial record